Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 13/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8297457 | 0.83 | TRPV1 (0.56) | TRPV1DRD2HTR2A | |
| SCHEMBL11888554 | 0.78 | TRPV1 (0.51) | TRPV1DRD4 | |
| SCHEMBL2841920 | 0.77 | TRPV1 (0.61) | TRPV1 | |
| SCHEMBL2843555 | 0.76 | TRPV1 (0.60) | TRPV1 | |
| SCHEMBL2844754 | 0.71 | LMNA (0.59) | TRPV1DRD4 | |
| SCHEMBL937918 | 0.70 | CYP1A2 (0.53) | TRPV1DRD4 | |
| SCHEMBL8299217 | 0.69 | TRPV1 (0.52) | TRPV1 | |
| SCHEMBL2838608 | 0.68 | RIPK1 (0.44) | TRPV1DRD4RIPK1 | |
| SCHEMBL1725284 | 0.66 | CYP1A2 (0.56) | DRD4 | |
| SCHEMBL1758382 | 0.66 | EPHX2 (0.64) | HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2091936-B1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA LP (US) | 2013-05-15 | — | — | EP | disclosed |
| EP-2091936-B1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA LP (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8389549-B2 | Substituted pyridines useful for treating pain | PURDUE PHARMA L.P. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389549-B2 | Substituted pyridines useful for treating pain | PURDUE PHARMA L.P. (US) | 2013-03-05 | — | — | US | disclosed |
| US-8389549-B2 | Substituted pyridines useful for treating pain | PURDUE PHARMA L.P. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2479173-A1 | Therapeutic agents useful for treating pain | Purdue Pharma LP (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-2479173-A1 | Therapeutic agents useful for treating pain | Purdue Pharma LP (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20100130552-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. | 2010-05-27 | — | — | US | disclosed |
| US-20100130552-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. | 2010-05-27 | — | — | US | disclosed |
| US-20100130552-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. | 2010-05-27 | — | — | US | disclosed |
| EP-2091936-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | Purdue Pharma LP (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008133973-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (DE) | 2008-11-06 | — | — | WO | disclosed |
| WO-2008133973-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130552-A1 | Therapeutic Agents Useful for Treating Pain | ARRB1, OPRK1, OPRD1 | TRPV1 48/4885DRD4 2300/4885RIPK1 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.